Activated Phosphoinositide 3 Kinase Delta Syndrome clinical trials

Explore recruiting activated phosphoinositide 3 kinase delta syndrome clinical trials.

Also recruiting in Europe

Activated Phosphoinositide 3 Kinase Delta Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension

Portugal, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 70 mg film coated tablet in healthy volunteers

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function

Germany, Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-Label Long-Term Extension

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Activated Phosphoinositide 3 Kinase Delta Syndrome trials by city

Activated Phosphoinositide 3 Kinase Delta Syndrome in Toronto Activated Phosphoinositide 3 Kinase Delta Syndrome in Vancouver Activated Phosphoinositide 3 Kinase Delta Syndrome in Montreal Activated Phosphoinositide 3 Kinase Delta Syndrome in Calgary Activated Phosphoinositide 3 Kinase Delta Syndrome in Edmonton Activated Phosphoinositide 3 Kinase Delta Syndrome in Ottawa Activated Phosphoinositide 3 Kinase Delta Syndrome in Winnipeg Activated Phosphoinositide 3 Kinase Delta Syndrome in Quebec City Activated Phosphoinositide 3 Kinase Delta Syndrome in Hamilton Activated Phosphoinositide 3 Kinase Delta Syndrome in Kitchener Activated Phosphoinositide 3 Kinase Delta Syndrome in London Activated Phosphoinositide 3 Kinase Delta Syndrome in Halifax Activated Phosphoinositide 3 Kinase Delta Syndrome in New York Activated Phosphoinositide 3 Kinase Delta Syndrome in Los Angeles Activated Phosphoinositide 3 Kinase Delta Syndrome in Chicago Activated Phosphoinositide 3 Kinase Delta Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease